Abstract
Glioblastoma (GBM) presents a significant public health challenge as the deadliest and most common malignant brain tumor in adults. Despite standard-of-care treatment, which includes surgery, radiation, and chemotherapy, mortality rates are high, underscoring the critical need for advancing GBM therapy. Over the past two decades, numerous clinical trials have been performed, yet only a small fraction demonstrated a benefit, raising concerns about the predictability of current preclinical models. Traditionally, preclinical studies utilize treatment-naïve tumors, failing to model the clinical scenario where patients undergo standard-of-care treatment prior to recurrence. Recurrent GBM generally exhibits distinct molecular alterations influenced by treatment selection pressures. In this review, we discuss the impact of treatment—surgery, radiation, and chemotherapy—on GBM. We also provide a summary of treatments used in preclinical models, advocating for their integration to enhance the translation of novel strategies to improve therapeutic outcomes in GBM.
Original language | English |
---|---|
Article number | 2638 |
Journal | Cancers |
Volume | 16 |
Issue number | 15 |
DOIs | |
State | Published - Aug 2024 |
Bibliographical note
Publisher Copyright:© 2024 by the authors.
Keywords
- glioblastoma
- preclinical models
- radiation therapy
- recurrent tumor
- resection
- reverse translation
- standard of care
- temozolomide
ASJC Scopus subject areas
- Oncology
- Cancer Research